The FDA recently issued an emergency use authorization for convalescent plasma to treat Covid-19. The idea is that plasma from a donor who has recovered from Covid-19 has antibodies that can help treat patients who are now in the early stages of infection. Does this work? Are there any downsides to this emergency approval? Let’s find out.
